The cost of cancer drugs is going through the roof. Reconsidering the large arsenal of drugs already available for other diseases as options for treating cancer is a unique opportunity for patients and for national healthcare systems. The continuing reduction in the cost of DNA sequencing is paving the way for ‘precision medicine’, and an increasing number of clinical trials are being designed specifically for patients with a certain genetic profile of their tumours. However, researchers and (…)